Bernard Gilly

Bernard Jacques Alex Gilly founded Grai Matter Labs SAS in 2016, where he worked as Chairman & President, Kainova Therapeutics, Inc. in 2001, where he worked as Director, Fovea Pharmaceuticals SA in 2005, where he worked as Chairman & Chief Executive Officer from 2005 to 2009, Gensight Biologics SA in 2012, where he worked as Director from 2023 to 2024, Tissium SA in 2013, where he worked as Non-Executive Chairman, Prophesee SA in 2014, where he is working as Chairman from 2014, iBionext SAS in 2015, where he is working as Chairman from 2015, Pixium Vision SA in 2011, where he worked as Chairman from 2015 to 2024, and BrainEver SAS in 2015, where he is working as Chairman & Chief Executive Officer from 2015.
Dr. Gilly also founded Sequoia Pharmaceuticals, Inc., Tilak Healthcare SAS, where he worked as Chairman & President, Cellzome AG, where he worked as Director-Executive Board, and CareX SA, where he worked as Chairman in 2007.
Dr. Gilly also currently works at Eye Tech Care SA, as Independent Chairman, Chronolife SAS, as Chairman & President, Promise Proteomics SAS, as Director, and T-Heart SAS, as Director.
Dr. Gilly also formerly worked at Transgene SA, as President & Chief Executive Officer from 1992 to 2000, Kutexis, as Chairman & Chief Executive Officer, Wavecom SA, as Director in 2009, Kala Bio, Inc., as Director, Enterome SA, as Non-Executive Director, Mnemosyne, as Director, bioMérieux SA, as Vice President-Research & Development, Sofinnova Partners SAS, as Partner from 2000 to 2005, Sanofi Pasteur SA, as Executive Vice President-Ophthalmology Division, Pasteur Mérieux Connaught, as Vice President-Research & Development, and Passage De L'Innovation, as President.
Dr. Gilly received his doctorate degree from the University of Rhode Island, Masters Business Admin degree from INSEAD, doctorate degree from the University of Rennes, and undergraduate degree from Ecole Nationale Supérieure Agronomique.